Topical non-invasive gene delivery using gemini nanoparticles in interferon-gamma-deficient mice.
Cutaneous gene therapy, although a promising approach for many dermatologic diseases, has not progressed to the stage of clinical trials, mainly due to the lack of an effective gene delivery system. The main objective of this study was to construct and evaluate gemini nanoparticles as a topical formulation for the interferon gamma (IFN-gamma) gene in an IFN-gamma-deficient mouse model. Nanoparticles based on the gemini surfactant 16-3-16 (NP16-DNA) and another cationic lipid cholesteryl 3beta-(-N-[dimethylamino-ethyl] carbamate) [Dc-chol] (NPDc-DNA) were prepared and characterized. Zetasizer measurement indicated a bimodal distribution of 146 and 468 nm average particle sizes for the NP16-DNA (zeta-potential +51 mV) nanoparticles and monomodal distribution of 625 nm (zeta-potential +44 mV) for the NPDc-DNA. Circular dichroism studies showed that the gemini surfactant compacted the plasmid more efficiently compared to the Dc-chol. Small-angle X-ray scattering measurements revealed structural polymorphism in the NP16-DNA nanoparticles, with lamellar and Fd3m cubic phases present, while for the NPDc-DNA two lamellar phases could be distinguished. In vivo, both topically applied nanoparticles induced higher gene expression compared to untreated control and naked DNA (means of 0.480 and 0.398 ng/cm(2) vs 0.067 and 0.167 ng/cm(2)). However, treatment with NPDc-DNA caused skin irritation, and skin damage, whereas NP16-DNA showed no skin toxicity. In this study, we demonstrated that topical cutaneous gene delivery using gemini surfactant-based nanoparticles in IFN-gamma-deficient mice was safe and may provide increased gene expression in the skin due to structural complexity of NP16 nanoparticles (lamellar-cubic phases).
Badea
Ildiko
I
College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
Wettig
Shawn
S
Verrall
Ronald
R
Foldvari
Marianna
M
D000818:Animals; D002784:Cholesterol / Q000031:analogs & derivatives / Q000737:chemistry; D002942:Circular Dichroism; D005240:Feasibility Studies; D005260:Female; D015870:Gene Expression; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000172:deficiency / Q000235:genetics; D051379:Mice; D018345:Mice, Knockout; D053758:Nanoparticles; D009690:Nucleic Acid Conformation; D010316:Particle Size; D010957:Plasmids / Q000737:chemistry* / Q000378:metabolism; D000644:Quaternary Ammonium Compounds / Q000737:chemistry*; D053838:Scattering, Small Angle; D012867:Skin / Q000378:metabolism; D013501:Surface-Active Agents / Q000737:chemistry*; D014961:X-Ray Diffraction
C520088:N,N'-bis(dimethylhexadecyl)-1,3-propanediammonium dibromide; D000644:Quaternary Ammonium Compounds; D013501:Surface-Active Agents; C070648:3-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol; D007371:Interferon-gamma; D002784:Cholesterol